Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Summary not available.
Summary not available.
Eli Lilly (NYSE: LLY) has announced a definitive agreement to sell its glucagon product BAQSIMI to Amphastar Pharmaceuticals (NASDAQ: AMPH) for $500 million at closing and an additional $125 million after one year. This divestiture aims to enhance the accessibility of BAQSIMI, the first nasal glucagon treatment for severe hypoglycemia in diabetes patients. BAQSIMI generated worldwide sales of $139.3 million in 2022, and the deal is expected to close in Q2 or Q3 2023. Both companies' boards have approved the agreement, which includes potential sales-based milestone payments of up to $450 million. Amphastar plans to invest in BAQSIMI to improve treatment access for those on insulin, aligning with its strategic focus on expanding its diabetes portfolio.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced a business update and a conference call scheduled for April 24, 2023, at 6:00 AM Pacific Time. Interested parties can join the call by calling 877-407-0989 or +1 201-389-0921 for international access. The live call will be available on the Amphastar Investors page, with a replay accessible post-event.
Amphastar focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products, primarily for clinical settings. The company also sells insulin API products. The press release includes forward-looking statements regarding financial performance, product development timelines, and market conditions, emphasizing the potential impact of external factors like COVID-19 and geopolitical events on its operations.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 12:45 PM Eastern Time. Key executives, including Bill Peters (CFO) and Jacob Liawatidewi (EVP of Corporate Administration), will engage in an Analyst-Moderated fireside chat. The event can be accessed via Amphastar’s website, where a recording will be available for 90 days post-presentation.
Amphastar specializes in developing and marketing generic and proprietary injectables, inhalation, and intranasal products, primarily used in clinical settings. The company also sells insulin active pharmaceutical ingredients. For further details, visit their website.
This announcement includes forward-looking statements regarding Amphastar's expectations for future business performance and market conditions.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced FDA approval for its naloxone hydrochloride nasal spray 4mg, aimed at treating opioid overdoses in both adults and children. This innovation is expected to alleviate the opioid crisis by improving access to critical treatment. In 2022, U.S. sales for naloxone nasal spray reached approximately $250 million. Amphastar's pipeline includes three ANDAs, three biosimilars, and six generics targeting markets exceeding $23 billion. The company has also filed 17 Drug Master Files, with multiple proprietary products in development, enhancing its position in the competitive pharmaceutical landscape.
Amphastar Pharmaceuticals reported strong fourth-quarter results for the period ending December 31, 2022, showcasing net revenues of $135.0 million, a 12% increase from the previous year. The company achieved a GAAP net income of $33.9 million, or $0.66 per share. For the full fiscal year, net revenues reached $499.0 million, up 14%, with GAAP net income totaling $91.4 million, or $1.74 per share. The growth was driven by increased sales of key products like epinephrine and Primatene MIST. Looking ahead, Amphastar plans to launch multiple new products to sustain growth.
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to announce its fourth-quarter earnings for 2022 on February 28, 2023, after market closure. A conference call will follow at 2:00 p.m. PT to discuss the financial results. Interested parties can join by dialing (877) 407-0989 or (201) 389-0921 for international calls. Amphastar specializes in developing and selling generic and proprietary injectable, inhalation, and intranasal products, focusing on hospital use. The company emphasizes that its future performance statements are forward-looking and subject to various uncertainties, including COVID-19 impacts and macroeconomic conditions.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will have Bill Peters, CFO, and Tony Marrs, Sr. VP of Regulatory Affairs, participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 11:00 AM ET. Access the webcast via Amphastar's website, available for 90 days post-event. Amphastar focuses on developing and selling challenging generic and proprietary products, mainly targeting hospital use. More info can be found at www.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announces participation in the Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16, 2022, at 3:50 PM GMT. Bill Peters, CFO, and Jacob Liawatidewi, Executive V.P., will represent the company. The presentation will be accessible on Amphastar's website for 90 days. Amphastar specializes in developing and selling generic and proprietary injectable and inhalation products, predominantly used in clinical settings.